
News|Videos|December 7, 2025
Navigating Drug Shortages and Alternative Therapies
Author(s)Judith Hey-Hadavi, Nicole Snow
Advertisement
Episodes in this series

Judith Hey-Hadavi, vice president of Medical Affairs at Worldwide Clinical Trials, and Nicole Snow, senior clinical pharmacy liaison at Olympia Pharmaceuticals, discuss the challenges of GLP-1 receptor agonist drug shortages and the role of compounded alternatives in patient care. They highlight safety concerns with compounded medications, including variable dosing, lack of standardized delivery devices, and the risk of counterfeit products. Both emphasize the importance of patient education, proper administration training, and monitoring supply chains to ensure safety and efficacy.
Advertisement
Related to this article

Liquid chromatography–tandem mass spectrometry (LC–MS/MS) reveals distinct sphingolipid patterns in anorexia and obesity.

Leon Niezen and Gert Desmet discuss uncertainty-driven LC method development, peak overlap, and moving from in silico to real data.

Leon Niezen and Gert Desmet describe how predictive uncertainty can make automated LC method development more reliable.

Liquid chromatography–mass spectrometry (LC–MS) serum profiling ties lysine compounds to lupus kidney disease.

Liquid chromatography-mass spectrometry (LC–MS) growth lifts Waters Q3; MOBILion ion mobility buy expands proteomics.

Liquid chromatography–tandem mass spectrometry (LC–MS/MS) measures galactose-1-phosphate in dried blood spots to monitor galactosemia.
Advertisement
Advertisement
Trending on LCGC International
1
AI/ML Now: Toxicity Prediction for Unknown LC–HRMS Features Using Machine Learning
2
LCGC Blog: Building a Career Series That Goes Beyond the Surface
3
From 9000 Clues to a Clinical Test: Mass Spectrometry-Driven Lipidomics for Early Cancer Detection
4
Testing Plastic Packaging for PFAS Without SPE: A Fast, Cost-Effective Direct Shoot LC-MS/MS Method on the QSight® 500 System That Meets Regulatory Requirements
5








